• Hyundai Bioscience Says Oral COVID Drug Combo Shows Efficacy

Hyundai Bioscience President Oh Sang-gi speaks during a press conference in Seoul. (Photo: Yonhap)

Biotech firm Hyundai Bioscience says its oral COVID-19 treatment candidate combined with dexamethasone showed high efficacy in animal testing.

The South Korean company is currently re-purposing niclosamide-based CP-COV03 as a potential treatment for coronavirus disease.

The investigative drug's indication includes influenza.

Company officials said the use of both CP-COV03 and dexamethasone resulted in efficacy against COVID-19 that is 2.1 times higher than using dexamethasone alone.

Hyundai Bioscience has won approval from local drug authorities to conduct a Phase 1 clinical trial of CP-COV03 in 18 adult patients.

Currently, dexamethasone, a corticosteroid that reduces inflammation in various parts of the body, and Remdesivir, which is developed by Gilead Sciences, are used to treat critically ill COVID-19 patients.

Please send comments to tbsefmnews@gmail.com / copyright © tbs. Unauthorized redistribution prohibited.

개인정보처리방침  l  영상정보처리기기방침  l  사이버 감사실  l  저작권 정책  l  광고 • 협찬단가표  l  시청자 위원회  l  정보공개

03909 서울특별시 마포구 매봉산로 31 S-PLEX CENTER | 문의전화 : 02-311-5114(ARS)
Copyright © Since 2020 Seoul Traffic Broadcasting. All Rights Reserved.